Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer

Inclusion Criteria: * Age: 18-75 years old * Primary and pathological diagnosis of rectal adenocarcinoma * Radiographic evaluation of initial resectable rectal cancer * T staging was determined by MRI as T3N+ or T4Nx * Distal border of the tumor must be located \< 12 cm from the anal verge * ECOG status: 0～1 * Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: Neutrophil count≥1.5×10\^9/L Platelet count≥90×10\^9/L Hemoglobin≥90g/L Total bilirubin (TBI) ≤ 1.5 \* ULN Alanine aminotransferase (ALT)≤2.5 \* ULN Aspartate aminotransferase (AST)≤2.5 \* ULN Alkaline phosphatase (ALP)≤2.5 \* ULN \- Signed informed consent; able to comply with study and/or follow- up procedures Exclusion Criteria: * Previous treatment with oxaliplatin, irinotecan or fluorouracil * Hypersensitivity to fluorouracil, oxaliplatin or irinotecan. * Clear indication of involvement of the pelvic side walls by imaging * With distant metastasis * A history of malignant rectal cancer (i. e. sarcoma, lymphoma, carcinoid, squamous cell carcinoma) or synchronous colon cancer * Cardiovascular disease that would preclude study treatment or follow-up; New York Heart Association class III or IV heart disease; active ischemic heart disease; myocardial infarction within the past 6 months; symptomatic arrhythmia uncontrolled hypertension. Unexplained syncope occurred within 3 months * Digestive system diseases that would preclude study treatment or follow-up within the past 6 months * Gastric ulcers or duodenal ulcers for the treatment of resistance; * 3 or 4 grade gastrointestinal bleeding / bleeding; * Gastrointestinal perforation / fistula; * Abdominal abscess; * Infectious or inflammatory bowel disease * HIV infection and/or active hepatitis B virus infection * Pregnant or lactating women. Fertile patients must use effective contraception * Any serious acute or chronic disease that can not be involved in the study or to influence the interpretation of the results of the study * Other intervention clinical trials were combined at the same time. * Nerve or mental abnormality affecting cognitive ability * Other malignancy except effectively treated squamous cell or basal cell skin cancer, * Other situations that the researchers think should be excluded